Hormone · Synthetic gonadotrophin-releasing hormone receptor antagonist
Ozarelix
Also known as D-63153
Also designated D-63153, this decapeptide antagonist supports studies of GnRHR signalling and receptor-dependent cellular responses.
- Length
- 10 amino acids
- Half-life
- Not well characterised
- Mechanism
- Ozarelix competitively antagonises GnRHR, inhibiting GnRH-triggered receptor signalling and downstream gonadotrophin secretion. Effects observed in non-pituitary cell systems require separate confirmation of receptor expression and pathway dependence.
- Studied in
- GnRHR assays, animal endocrine models and exploratory tumour-cell studies investigate Ozarelix pharmacology and the context dependence of cellular responses.
About Ozarelix
Ozarelix, identified in research literature as D-63153, is a synthetic GnRH antagonist built on a modified decapeptide scaffold. Non-native residues and stereochemical substitutions distinguish it from endogenous GnRH and change how it engages the receptor. Its established endocrine mechanism is blockade of GnRHR-mediated signalling. Laboratory investigations have also extended into non-pituitary cellular systems, where researchers examine whether observed responses reflect GnRH receptor biology or additional, context-dependent cellular processes.
Extra-pituitary findings require more cautious interpretation than inhibition in a well-characterised GnRHR assay. Receptor transcript detection alone does not demonstrate functional receptor protein at the cell surface, and altered proliferation does not establish a receptor-mediated mechanism. Useful controls include receptor-negative cells, genetic perturbation and independent signalling measurements. Comparisons across cell lines should also account for peptide stability in culture medium, serum composition and the duration of exposure during the experiment.
Laboratory notes
- Cross-reference D-63153 with Ozarelix when reviewing literature, while checking the sequence and salt form of the experimental material.
- Verify functional GnRHR expression rather than relying only on transcript measurements in non-pituitary models.
- Pair proliferation assays with viability and receptor-dependence controls to avoid assigning non-specific effects to GnRHR antagonism.
Storage and reconstitution basics: storage guide.
Questions about Ozarelix
What does D-63153 refer to?
D-63153 is a research designation used for Ozarelix.
Does a tumour-cell response prove GnRHR involvement?
No. Receptor-dependent signalling must be established independently, ideally using genetic controls and orthogonal functional assays.
Why check stability in culture medium?
Degradation or binding to medium components can change the available intact peptide concentration and complicate interpretation of cellular responses.
Is Ozarelix for human use?
No. It is supplied strictly for in-vitro laboratory research and is not for human or animal consumption.
Related research peptides
All products are sold for laboratory research use only. Not for human consumption, not a medicine, not for diagnosing, treating or preventing any condition.